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Abstract
Background: Pancreatic cancer is one of the leading
causes of cancer-related death. Using DNA gene expres-
sion analysis based on a custom made Affymetrix cancer
array, we investigated the expression pattern of both pri-
mary and established pancreatic carcinoma cell lines.
Methods: We analyzed the gene expression of 5 estab-
lished pancreatic cancer cell lines (AsPC-1, BxPC-3, Ca-
pan-1, Capan-2 and HPAF II) and 5 primary isolates, 1 of
them derived from benign pancreatic duct cells. Results:
Out of 1,540 genes which were expressed in at least 3
experiments, we found 122 genes upregulated and 18
downregulated in tumor cell lines compared to benign
cells with a fold change 13. Several of the upregulated
genes (like Prefoldin 5, ADAM9 and E-cadherin) have
been associated with pancreatic cancer before. The other
differentially regulated genes, however, play a so far
unknown role in the course of human pancreatic carcino-
ma. By means of immunohistochemistry we could show
that thymosin ß-10 (TMSB10), upregulated in tumor cell
lines, is expressed in human pancreatic carcinoma, but
not in non-neoplastic pancreatic tissue, suggesting a role
for TMSB10 in the carcinogenesis of pancreatic carcino-
ma. Conclusion: Using gene expression profiling of pan-
creatic cell lines we were able to identify genes differen-
tially expressed in pancreatic adenocarcinoma, which
might contribute to pancreatic cancer development.
Copyright © 2005 S. Karger AG, Basel and IAP
Introduction
Pancreatic cancer is the fourth leading cause of cancer
death in the United States. It can be estimated that
annually 28,000 people die from pancreatic cancer [1].
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The incidence has slightly increased over the past de-
cades, being 8.1 for men and 5.4 for women in Germany
[2]. About 80% of patients with pancreatic carcinoma
present with an irresectable tumor at the time of diagno-
sis. Chemotherapy and radiation have not been able to
increase the survival rate, and curability of the disease
strongly depends on early diagnosis. Although several
molecular alterations have been associated with pancreat-
ic carcinoma, a much larger number of genes are involved
in processes leading to cell transformation and, in conse-
quence, pancreatic cancer.
DNA microarray technology has proven to be a useful
tool to screen the differential mRNA expression pattern
of normal and carcinoma cells [3–7]. While for other
tumor entities a small piece from the tumor can be
excised, homogenized and the mRNA extracted to be ana-
lyzed, the morphological growth peculiarities of pancreat-
ic carcinoma impede this approach. Due to the character-
istic host desmoplastic reaction to the tumor, only a small
fraction of the mRNA extracted from carcinomatous
tumor will descend from the transformed ductal cells. A
majority will represent the expression profile of the sur-
rounding stromal cells. Cell lines can, however, be used as
model systems for tumor development and for the analy-
sis of new treatment options. We therefore determined
the differential gene expression in pancreatic carcinoma
from established tumor cell lines and primary isolates
using a custom made Affymetrix GeneChip. Within the
set of genes we identified 140 genes as differentially
expressed and validated the overexpression of thymosin
ß-10 (TMSB10) within ductal pancreatic adenocarcino-
mas by immunohistochemistry.
Materials and Methods
Cell Lines and RNA Preparation
The ATCC (American Type Culture Collection) cell lines AsPC-1
(CRL-1682), BxPC-3 (CRL-1687), Capan-1 (HTB-79), Capan-2
(HTB-80) and HPAF II (CRL-1997) were a gift from Dr. M. Schmitz,
Institute of Immunology, University of Dresden.
UKEAC-99 was obtained from a patient who underwent Whip-
ple’s operation for papillary carcinoma of intermediate differentia-
tion [8]. PI3 was obtained from a metastasis in the omentum of a
patient with pancreatic adenocarcinoma of intermediate differentia-
tion. PI4 was derived from ascites fluid of a patient with pancreatic
adenocarcinoma, and PI5 was obtained from a lung metastasis from
a patient with pancreatic adenocarcinoma. All cell lines were tested
for tumorigenicity and caused pancreatic adenocarcinoma after
injection into mice which were histologically confirmed by a patholo-
gist. Chromosomal analysis was performed with all cell lines.
ATCC cells and primary isolates were propagated in RPMI 1640
medium (Gibco) supplemented with 10% fetal bovine serum (Gib-
co), 2 mM glutamine (Gibco), nonessential amino acids (5 ml/l), and
penicillin/streptomycin (10,000 units/ml penicillin and 10 mg/ml
streptomycin, 10 ml/l medium; Sigma) and passaged before con-
fluency.
The hPDC was obtained from the main pancreatic duct of a
patient undergoing surgery for chronic pancreatitis. The cells were
propagated in Keratinocyte SFM supplemented with 5 ng/ml EGF,
50 Ìg/ml BPE, 50 Ìg/ml gentamycin, 0.25 Ìg/ml Fungizone; 500 Ìl/
60 mm dish (Invitrogen, Karlsruhe, Germany) [9]. All cells were
lysed in a guanidine thiocyanate buffer with 2% ß-mercaptoethanol
added (Promega, Heidelberg, Germany).
Poly A+ RNA was prepared with a PolyATtract 1000 kit (Prome-
ga) according to the manufacturer’s recommendations. For each
sample the cDNA synthesis and in vitro transcription were per-
formed according to the Affymetrix user manual using 500 ng of the
isolated RNA. In brief, cDNA synthesis was initiated using the Affy-
metrix T7-oligo-dT promotor-primer combination at 0.1 mM. From
this first strand cDNA, the second strand synthesis was generated
with internal priming. The in vitro transcription was performed with
Ambion’s Megascript kit (Ambion, Huntington, UK), as recom-
mended by the manufacturer. During the in vitro transcription, bio-
tin-labeled nucleotides were incorporated into the aRNA. Hybridiza-
tion and detection of the labeled aRNA on the metg001A GeneChip
were performed according to Affymetrix’s instructions.
Chip Design and Data Analysis
The custom metg001A GeneChip used in this study consists of
6,117 probe sets resembling 3,023 cDNA fragments. The cDNA frag-
ments were chosen from a data mining approach to characterize the
expression of cancers by an electronic Northern blot [10, 11]. In addi-
tion genes of signal transduction cascades, which are implicated in
cancer development and progression, like the wnt cascade, were
selected.
The background was computed as the mean of the 2% darkest
feature intensities. After background correction the arrays were nor-
malized by dividing each feature of a given GeneChip by the median
value derived from all features of the same GeneChip. To generate
the representative expression value we used the 75% quartile of the
ranked intensities from the 20 perfect-matching oligonucleotides of a
probe set, in an approach similar to that of Irizarry et al. [12]. To
distinguish signal from noise we applied the Wilcoxon signed rank
test to each probe set. The probe set was labeled as present if the
result of the Wilcoxon signed rank was below 0.01.
To determine the relative difference in expression between the
tumor cell lines and the benign ductal cells, the mean expression val-
ue in the tumor cell lines was calculated and compared to the expres-
sion value in the benign ductal cells. Genes were called as differen-
tially expressed when the change fold was above 3 and when the gene
was called present in at least 3 cell lines as well. Genes are listed
according to the difference ratio.
Complete linkage clustering of the differentially expressed genes
was done using the Genecluster/Treeview software package (http://
rana.lbl.gov/EisenSoftware.htm) using Spearman rank correlation as
distance matrix (fig. 1).
Immunohistochemical Staining
Tumor tissue was selected from 55 consecutive cases of pancreat-
ic ductal adenocarcinoma, whereas adenocarcinoma of the ampulla
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of Vater or the distal ductus choledochus was not included. Patients
were operated on at ages from 34 to 80 years; 27 were male and 28
were female.
Four-micron sections were cut from the formalin-fixed, paraffin-
embedded, pancreatic adenocarcinoma tissue. The sections were
mounted on superfrost slides (Menzel Gläser, Braunschweig, Germa-
ny), dewaxed with xylene and gradually hydrated. Antigen was
exposed by heating the sections under high pressure in Tris-EDTA-
citrate buffer. The primary goat polyclonal anti-human TMSB10
antibody [13] was diluted 1:500 in PBS containing 2% horse serum
(Vector Laboratories, Burlingame, Calif., USA). After incubation for
45 min, the reaction was visualized with a biotinylated anti-goat anti-
body (5 Ìg/ml, Vector Laboratories) and avidin-biotin-peroxidase
(ABC ELITE, Vector Laboratories). Diaminobenzidine served as
chromogen. Afterwards the slides were briefly counterstained with
hematoxylin. The primary antibody was omitted for the negative
control. Unspecific goat IgG at the same concentration as the specific
Ig were used as isotype controls to assure the specificity of the reac-
tion. Staining intensity was evaluated semi-quantitatively as nega-
tive, weak, moderate or strong. The final results, however, were
recorded as positive or negative staining only.
Results
Out of the 3,023 cDNA fragments interrogated by gene
expression profiling 1,540 genes were rated as present in
at least 3 cell lines. Difference in expression was rated sig-
nificant if the ratio was greater than 3 and if the gene was
detected as present in at least 3 cell lines as well. Of the
1,540 genes, 122 were upregulated and 18 were downregu-
lated in respect to the benign cells. Seven genes were
upregulated and 3 genes downregulated in primary iso-
lates only. One gene was upregulated in ATCC cell lines
only and not in primary isolates (table 1).
Using hierarchical clustering, we generated a heat map
of the gene expression of the identified genes to visualize
the gene expression within each experiment (fig. 1). Genes
encoding proteins of known function have been classified
according to functional categories (fig. 2). Within these
categories we found that genes associated with cellular
proliferation are commonly upregulated. Within the 122
genes we identified several genes, such as ADAM9 or E-
cadherin, with known function in carcinoma of the pan-
creas or other tissues (table 2).
Fig. 1. Hierarchical clustering of differentially expressed genes in
pancreatic cells. Black squares indicate that the gene was called
absent by the software.
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Table 1. Genes differentially expressed within the pancreatic cell lines analyzed
A. Genes upregulated in tumor
Name Symbol Unigene ID MV/hPDC BxPC-3 AsPC-1 Capan-1 Capan-2 HPAF2 PI1 PI3 PI4 PI5
CDC28 protein kinase regulatory subunit 2 CKS2 Hs.83758 12.11 15.15 6.87 12.88 14.36 9.50 17.58 20.53 9.75 2.32
Thymosin ß-10 TMSB10 Hs.76293 12.08 9.47 12.60 8.83 9.40 10.13 10.89 17.13 17.88 12.40
Similar to transmembrane protein AMIGO3 – Hs.121520 10.13 5.88 6.84 10.03 5.67 3.52 21.84 10.11 8.60 18.69
CSE1 chromosome segregation 1-like (yeast) CSE1L Hs.90073 9.59 5.00 8.35 6.89 8.89 6.89 11.91 19.69 13.42 5.27
Capping protein (actin filament)
muscle Z-line, ·2 CAPZA2 Hs.75546 9.52 6.19 7.46 8.39 4.58 6.22 16.97 14.90 10.53 10.47
Eukaryotic translation initiation factor 3,
subunit 3 Á, 40 kDa EIF3S3 Hs.58189 9.48 4.16 9.06 6.98 12.16 10.22 14.32 9.85 7.59 11.02
Small nuclear ribonucleoprotein polypeptide G SNRPG Hs.77496 9.39 8.33 6.89 10.82 7.54 7.71 11.25 15.11 10.69 6.17
Prefoldin 5 PFDN5 Hs.288856 9.22 6.91 6.33 6.12 6.36 8.18 13.18 14.29 11.37 10.23
Asparagine synthetase ASNS Hs.75692 8.65 5.55 4.14 12.45 2.25 7.68 14.78 5.05 7.29 18.68
Calmodulin 1 (phosphorylase kinase, ‰) CALM1 Hs.374441 7.91 4.89 7.19 8.80 9.57 5.45 10.59 9.17 7.83 7.70
Proliferating cell nuclear antigen PCNA Hs.78996 7.42 11.41 4.99 5.51 6.65 5.84 8.30 12.16 10.13 1.79
Cyclin-dependent kinase 4 CDK4 Hs.95577 7.35 6.64 4.81 7.07 8.95 7.57 8.43 9.53 7.69 5.46
Dyskeratosis congenita 1, dyskerin DKC1 Hs.4747 7.24 6.04 6.28 4.94 8.05 3.23 9.70 11.38 9.12 6.39
Zinc finger protein 9 (a cellular retroviral
nucleic-acid-binding protein) ZNF9 Hs.2110 7.23 8.60 5.98 5.98 6.27 5.16 9.26 8.47 6.54 8.80
Complement component 5 receptor 1
(C5a ligand) C5R1 Hs.2161 7.15 0.43 11.57 1.39 17.72 5.63 12.30 10.67 4.68
NADH dehydrogenase (ubiquinone)
1· subcomplex, 4, 9 kDa NDUFA4 Hs.50098 7.04 6.38 6.52 6.87 5.27 5.76 6.12 9.48 10.37 6.62
Mitochondrial ribosomal protein L13 MRPL13 Hs.333823 6.93 6.04 6.46 4.39 6.08 5.42 12.74 10.33 6.50 4.40
Profilin 1 PFN1 Hs.408943 6.82 7.48 5.40 4.42 6.04 4.12 7.49 11.64 7.91 6.85
Hypothetical protein MGC40157 MGC40157 Hs.295362 6.67 5.98 5.82 3.44 6.86 8.44 4.14 9.00 6.10 10.26
A disintegrin and metalloproteinase domain 9
(meltrin Á) ADAM9 Hs.2442 6.67 4.47 7.26 5.72 5.73 10.26 4.50 9.96 6.90 5.21
Finkel-Biskis-Reilly murine sarcoma virus
(FBR-MuSV) ubiquitously expressed
(fox derived); ribosomal protein S30 FAU Hs.177415 6.66 6.20 4.77 6.76 4.94 5.37 5.72 9.02 10.68 6.51
PEST-containing nuclear protein PCNP Hs.71618 6.61 5.41 5.58 3.49 4.98 3.82 9.36 12.11 9.95 4.78
Epithelial membrane protein 3 EMP3 Hs.9999 6.59 2.73 2.69 1.24 3.08 1.59 8.94 15.04 10.72 13.24
RAD21 homolog (S. pombe) RAD21 Hs.81848 6.58 6.22 5.27 3.99 5.94 4.27 12.34 8.84 7.38 5.01
Ribosomal protein L10a RPL10A Hs.425293 6.50 4.14 4.72 4.85 4.82 6.89 9.70 8.22 7.47 7.72
Isocitrate dehydrogenase 1 (NADP+), soluble IDH1 Hs.11223 6.27 4.23 5.43 11.53 5.90 5.00 9.31 4.11 4.29 6.62
High-mobility group nucleosomal-binding
domain 2 HMGN2 Hs.181163 6.18 7.59 5.22 5.45 5.21 4.46 6.86 9.06 7.35 4.43
DEAD/H (Asp-Glu-Ala-Asp/His)
box polypeptide 39 DDX39 Hs.311609 6.14 3.52 4.86 5.49 7.37 2.98 8.26 11.36 7.65 3.78
NADH dehydrogenase (ubiquinone)
1ß subcomplex, 8, 19 kDa NDUFB8 Hs.198273 5.90 4.88 5.00 4.28 7.50 7.08 6.32 8.96 5.35 3.67
Fibrillarin FBL Hs.99853 5.77 6.28 6.84 3.79 4.29 4.88 7.59 7.08 6.91 4.27
Proteasome (prosome. macropain)
subunit, · type, 2 PSMA2 Hs.411773 5.54 3.70 3.34 4.43 3.79 4.60 8.39 9.01 7.58 5.02
Hypothetical protein FLJ14668 FLJ14668 Hs.334644 5.51 5.43 4.06 4.64 3.85 4.03 5.54 8.45 8.16 5.40
Neural precursor cell expressed,
developmentally downregulated 5 NEDD5 Hs.155595 5.45 4.89 8.06 8.57 5.82 4.46 4.71 4.77 3.69 4.09
Splicing factor 3b, subunit 1, 155 kDa SF3B1 Hs.334826 5.35 4.15 4.76 5.56 4.28 5.35 7.03 7.03 5.93 4.07
Ras homolog gene family, member A ARHA Hs.77273 5.25 2.14 3.96 7.55 4.38 2.56 8.40 7.53 5.10 5.60
Apoptosis-related protein APR-3 APR-3 Hs.9527 5.23 4.00 5.43 5.89 4.29 3.92 6.72 5.99 5.02 5.83
Triosephosphate isomerase 1 TPI1 Hs.83848 5.21 6.16 5.27 4.36 7.60 5.08 5.54 6.73 3.82 2.34
H1 histone family, member 0 H1F0 Hs.226117 5.20 1.46 3.87 4.69 3.14 3.35 7.37 6.39 6.41 10.15
TAF9 RNA polymerase II, TATA-box-binding 
protein (TBP)-associated Factor, 32 kDa TAF9 Hs.60679 5.17 3.16 4.53 2.64 4.94 3.43 7.89 5.98 5.22 8.79
Thioredoxin-interacting protein TXNIP Hs.179526 5.16 5.30 5.40 3.15 1.65 5.01 3.14 5.57 3.87 13.31
Cytochrome b-245, · polypeptide CYBA Hs.68877 5.13 4.53 4.95 5.43 3.89 4.19 4.50 7.07 6.50 5.12
Lymphocyte antigen 6 complex, locus E LY6E Hs.77667 5.13 4.96 6.29 3.91 3.70 2.68 6.75 8.91 5.29 3.64
Similar to S. cerevisiae RER1 RER1 Hs.40500 5.03 2.80 5.53 3.29 3.92 3.91 6.53 9.09 5.33 4.90
Ribosomal protein L4 RPL4 Hs.286 5.01 5.27 4.65 4.96 3.55 3.82 4.11 6.39 7.68 4.68
Cathepsin C CTSC Hs.10029 5.00 4.53 3.07 2.46 6.92 4.52 7.05 6.78 6.75 2.92
Hypoxanthine phosphoribosyltransferase 1
(Lesch-Nyhan syndrome) HPRT1 Hs.82314 4.95 5.13 2.72 3.79 2.94 3.16 8.76 8.08 6.23 3.71
Actin-related protein 2/3 complex, subunit 1B, 
41 kDa ARPC1B Hs.433506 4.94 2.49 5.62 3.84 2.47 3.24 4.82 7.59 8.92 5.48
Annexin A4 ANXA4 Hs.422986 4.92 1.70 10.68 5.50 1.09 4.99 9.05 5.36 3.63 2.27
Cofilin 1 (nonmuscle) CFL1 Hs.180370 4.89 4.52 2.86 3.41 4.71 3.64 6.26 9.61 5.48 3.49
Chaperonin-containing TCP1, subunit 5 (Â) CCT5 Hs.1600 4.85 4.45 3.36 5.52 5.02 2.72 5.77 7.00 6.83 2.99
Ribosomal protein L3 RPL3 Hs.119598 4.84 4.86 4.69 4.77 3.63 3.59 4.20 6.55 6.54 4.77
Rho GDP dissociation inhibitor (GDI) ß ARHGDIB Hs.83656 4.81 5.40 2.16 4.60 3.70 6.08 5.75 5.90 5.88 3.82
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Table 1 (continued)
Name Symbol Unigene ID MV/hPDC BxPC-3 AsPC-1 Capan-1 Capan-2 HPAF2 PI1 PI3 PI4 PI5
Chromosome 15 open reading frame 15 C15orf15 Hs.284162 4.81 4.61 2.24 6.37 2.59 4.94 7.03 4.59 4.61 6.31
unc-84 homolog A (C. elegans) UNC84A Hs.381143 4.76 5.66 5.57 4.02 3.36 3.86 5.99 4.03 4.87 5.48
Siah-interacting protein SIP Hs.27258 4.73 2.65 3.26 2.76 4.49 3.88 7.11 7.59 6.68 4.17
Ribosomal protein, large, P1 RPLP1 Hs.424299 4.71 5.14 4.60 4.84 3.51 2.83 4.06 6.37 6.48 4.62
CGI-119 protein CGI-119 Hs.283670 4.70 3.29 4.24 3.48 2.09 6.03 6.65 6.33 5.45 4.70
Programmed cell death 10 PDCD10 Hs.28866 4.53 2.96 2.32 5.44 3.86 4.32 6.17 5.84 4.67 5.15
Adducin 3 (Á) ADD3 Hs.324470 4.46 3.95 7.51 4.35 3.07 4.37 6.95 3.51 3.68 2.77
Actin-related protein 2/3 complex, subunit 5,
16 kDa ARPC5 Hs.82425 4.42 3.77 2.89 3.54 3.75 2.64 5.70 7.60 5.97 3.97
Ribosomal protein S13 RPS13 Hs.165590 4.42 4.12 4.18 4.16 3.18 3.27 3.68 5.80 7.21 4.19
Family with sequence similarity 3, member C FAM3C Hs.29882 4.33 2.94 2.60 3.84 5.91 3.09 6.01 4.39 4.44 5.77
Eukaryotic translation initiation factor 3,
subunit 5 Â, 47 kDa EIF3S5 Hs.381255 4.27 3.21 2.80 3.28 4.30 3.97 5.43 5.50 5.19 4.73
Protein phosphatase 2 (formerly 2A), catalytic 
subunit, ß isoform PPP2CB Hs.80350 4.23 3.84 5.62 2.67 3.37 1.72 5.55 6.23 4.23 4.82
HMT1 hnRNP methyltransferase-like 2
(S. cerevisiae) HRMT1L2 Hs.20521 4.23 4.56 3.58 3.76 3.36 3.78 3.33 5.91 5.11 4.63
Prohibitin PHB Hs.75323 4.20 2.42 2.66 6.85 2.70 4.05 4.91 6.41 5.45 2.36
Chaperonin-containing TCP1, subunit 8 ( ) CCT8 Hs.15071 4.15 3.00 4.41 2.57 4.72 3.59 6.80 4.29 4.21 3.74
Immediate early response 3 IER3 Hs.76095 4.14 1.95 2.29 2.36 2.03 2.23 5.25 7.53 6.24 7.42
Peroxiredoxin 4 PRDX4 Hs.83383 4.10 3.26 5.38 3.07 4.51 3.53 5.58 5.25 3.84 2.43
Sapiens cDNA: FLJ23477 fis, clone HSI15732 – Hs.145362 4.07 5.20 3.64 2.55 2.87 3.79 3.93 5.78 5.26 3.57
Heterogeneous nuclear ribonucleoprotein K HNRPK Hs.129548 4.06 2.55 3.70 3.81 3.83 3.12 5.42 5.42 4.40 4.33
MCM7 minichromosome maintenance
deficient 7 (S. cerevisiae) MCM7 Hs.77152 4.03 4.32 2.58 5.79 3.69 3.74 4.72 4.96 4.27 2.20
– EST 3.95 4.04 4.16 2.30 3.12 2.75 3.64 5.69 5.69 4.15
Membranecofactor protein (CD46, trophoblast-
lymphocyte cross-reactive antigen) MCP Hs.83532 3.94 4.10 3.10 3.85 4.53 4.52 5.34 3.85 2.85 3.33
Mitochondrial ribosomal protein L42 MRPL42 Hs.112110 3.91 3.17 1.89 4.70 2.65 3.19 5.42 6.00 4.18 3.95
Heat shock 70 kDa protein 8 HSPA8 Hs.180414 3.90 3.46 4.79 2.91 3.39 3.71 4.34 4.66 3.40 4.46
NADH dehydrogenase (ubiquinone)
1ß subcomplex, 9, 22 kDa NDUFB9 Hs.15977 3.89 2.62 2.74 4.36 2.91 2.76 5.23 5.56 5.12 3.70
Ribosomal protein L7 RPL7 Hs.153 3.85 2.22 3.56 3.62 3.15 3.35 3.66 5.57 5.46 4.10
Dynein, cytoplasmic, light polypeptide 2A DNCL2A Hs.100002 3.77 2.36 4.93 2.56 4.09 2.96 2.95 4.57 4.03 5.51
Matrin 3 MATR3 Hs.78825 3.76 2.79 3.79 2.57 2.90 3.21 5.08 5.33 4.36 3.82
Lysosomal-associated protein transmembrane 4· LAPTM4A Hs.111894 3.74 2.50 6.00 3.71 3.11 3.68 4.36 3.58 2.94 3.83
KIAA0152 gene product KIAA0152 Hs.181418 3.73 3.18 4.21 3.72 2.47 2.43 5.42 5.34 4.46 2.34
BUB3 budding uninhibited by benzimidazoles 
3 homolog (yeast) BUB3 Hs.40323 3.72 3.45 1.81 2.30 4.02 4.06 5.36 5.85 4.28 2.34
Tubulin-specific chaperone a TBCA Hs.433254 3.71 1.81 2.84 2.14 2.40 2.54 6.13 5.76 5.90 3.83
Ras-related C3 botulinum toxin substrate 1 
(rho family, small GTP-binding protein Rac1) RAC1 Hs.173737 3.67 2.20 3.04 1.96 2.76 1.90 4.90 5.30 5.16 5.76
TERA protein TERA Hs.180780 3.66 2.14 2.97 1.48 2.26 3.02 5.27 5.54 4.90 5.33
Farnesyl diphosphate synthase (farnesyl
pyrophosphate synthetase, dimethylallyl-
transtransferase, geranyltranstransferase) FDPS Hs.335918 3.65 3.54 2.24 4.30 6.03 4.63 3.73 2.61 3.00 2.74
Poly(rC)-binding protein 2 PCBP2 Hs.63525 3.64 3.72 3.35 2.38 3.78 4.39 3.71 4.43 3.51 3.46
Cytochrome C oxidase subunit VIc COX6C Hs.351875 3.59 3.35 2.74 2.29 3.49 3.27 4.71 5.28 4.39 2.84
APEX nuclease (multifunctional DNA repair 
enzyme) 1 APEX1 Hs.73722 3.59 2.45 2.12 2.46 3.08 3.70 4.68 5.45 4.77 3.56
ATPase, H+ transporting, lysosomal 21 kDa, V0
subunit c ATP6V0B Hs.7476 3.57 3.59 2.85 5.19 5.20 3.01 2.73 4.10 2.70 2.76
EST 3.57 0.00 1.52 0.00 3.15 5.51 6.73 4.52 4.95 5.73
Hypothetical protein MGC14151 MGC14151 Hs.333414 3.54 2.67 2.53 4.19 3.22 4.41 3.97 4.79 4.51 1.59
Cathepsin B CTSB Hs.297939 3.53 2.61 5.75 1.95 2.83 2.87 3.28 4.19 3.80 4.50
Prostatic-binding protein PBP Hs.80423 3.52 2.79 3.35 2.71 2.12 3.20 4.40 6.36 4.17 2.57
Stathmin 1/oncoprotein 18 STMN1 Hs.406269 3.51 2.19 3.72 2.57 2.60 1.66 3.58 6.87 6.03 2.38
Activated RNA polymerase II transcription 
cofactor 4 PC4 Hs.349506 3.50 2.76 1.81 3.25 2.41 3.60 4.04 5.67 4.30 3.69
NADH dehydrogenase (ubiquinone)
1ß subcomplex, 4, 15 kDa NDUFB4 Hs.227750 3.50 3.24 2.62 3.05 3.98 3.98 4.11 4.17 3.43 2.93
Uncharacterized hypothalamus protein 
HT007 HT007 Hs.24371 3.50 3.47 1.65 3.87 2.82 3.08 4.95 4.24 4.09 3.33
Proteasome (prosome. macropain) subunit,
· type, 6 PSMA6 Hs.410276 3.50 3.66 2.30 4.30 1.58 2.97 3.56 5.09 5.14 2.87
ATPsynthase, H+ transporting, mitochondrial 
F0 complex, subunit d ATP5H Hs.49018 3.46 2.15 2.13 1.96 3.15 3.32 5.50 5.35 4.39 3.17
Barrier to autointegration factor 1 BANF1 Hs.433759 3.44 3.93 2.13 2.66 2.62 3.24 4.55 5.77 3.18 2.91
Stearoyl-CoA desaturase (‰-9-desaturase) SCD Hs.119597 3.44 5.59 2.76 3.28 3.96 2.82 3.84 3.19 3.00 2.51
Chaperonin-containing TCP1, subunit 6A (˙) CCT6A Hs.82916 3.42 2.73 2.40 3.11 2.81 2.36 4.46 4.98 4.11 3.77
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Table 1 (continued)
Name Symbol Unigene ID MV/hPDC BxPC-3 AsPC-1 Capan-1 Capan-2 HPAF2 PI1 PI3 PI4 PI5
Interferon, ·-inducible protein (clone IFI-15K) G1P2 Hs.432233 3.41 2.95 4.58 3.91 5.27 3.73 2.29 3.22 2.57 2.15
Peroxiredoxin 5 PRDX5 Hs.31731 3.39 3.36 2.17 2.47 2.33 2.85 3.89 5.17 4.12 4.12
ATPsynthase, H+ transporting, mitochondrial 
F0 complex, subunit f, isoform 2 ATP5J2 Hs.235557 3.36 4.04 1.31 4.50 3.62 3.87 4.48 3.96 2.90 1.59
Ribosomal protein S9 RPS9 Hs.180920 3.33 3.34 3.11 3.23 2.31 2.52 2.68 4.22 5.49 3.05
X-ray repair complementing defective repair 
in Chinese hamster cells 5 (double-strand-
break rejoining; Ku autoantigen, 80 kDa) XRCC Hs.84981 3.29 1.88 2.91 2.26 3.00 2.26 5.36 5.03 3.90 3.02
Chromosome 20 open reading frame 43 C20orf43 Hs.182281 3.29 3.69 3.15 2.99 3.03 2.89 3.08 4.21 3.15 3.43
Glioma tumor suppressor candidate region 
gene 2 GLTSCR2 Hs.421907 3.28 2.88 3.91 1.89 2.42 2.68 3.55 3.42 4.19 4.55
Small nuclear ribonucleoprotein
D2 polypeptide 16.5 kDa SNRPD2 Hs.424327 3.25 3.27 3.06 3.13 2.35 2.59 2.76 4.24 5.06 2.83
Defender against cell death 1 DAD1 Hs.82890 3.24 3.09 2.87 2.70 3.13 3.59 3.98 3.95 2.59 3.30
Protein disulfide isomerase-related protein P5 Hs.182429 3.24 1.98 3.73 2.83 2.80 3.16 4.71 4.27 3.04 2.67
Cell death-regulatory protein GRIM19 GRIM19 Hs.279574 3.23 2.39 2.75 2.88 2.60 2.19 4.07 6.15 3.45 2.60
Death-associated protein 3 DAP3 Hs.159627 3.17 2.19 1.52 2.54 2.98 2.54 3.42 5.04 4.62 3.71
Inorganic pyrophosphatase 2 PPA2 Hs.5123 3.17 3.79 1.86 3.20 2.56 2.93 4.30 4.06 3.93 1.89
Poly(A)-binding protein, cytoplasmic 1 PABPC1 Hs.172182 3.16 2.73 2.82 2.81 3.30 2.72 3.96 3.17 3.24 3.65
Ribosomal protein L13 RPL13 Hs.431392 3.14 3.33 2.95 3.13 2.24 2.44 2.59 4.08 4.56 2.96
Guanine-nucleotide-binding protein
(G protein), Á12 GNG12 Hs.8107 3.13 2.81 3.22 2.23 2.40 3.71 4.11 3.53 3.32 2.84
CDC10 cell division cycle 10 homolog
(S. cerevisiae) CDC10 Hs.184326 3.10 2.68 2.38 1.95 2.42 2.45 4.84 4.53 3.85 2.82
Anaplastic lymphoma kinase (Ki-1) ALK Hs.9614 3.10 2.49 2.67 2.21 2.49 2.51 3.80 4.89 4.09 2.77
B. Genes downregulated in tumor cell lines
Name Symbol Unigene ID MV/hPDC BxPC-3 AsPC-1 Capan-1 Capan-2 HPAF2 PI1 PI3 PI4 PI5
Thrombospondin 1 THBS1 Hs.87409 0.31 0.60 0.10 0.13 0.52 0.29 0.30 0.22 0.33
Leucine-rich repeat-containing 8 LRRC8 Hs.173484 0.31 0.51 0.22 0.48 0.20 0.24 0.25 0.29 0.29
Phosphoprotein enriched in astrocytes 15 PEA15 Hs.194673 0.29 0.24 0.19 0.26 0.32 0.21 0.21 0.38 0.40 0.40
Coatomer protein complex, subunit · COPA Hs.75887 0.29 0.25 0.25 0.32 0.24 0.30 0.32 0.32 0.31 0.31
Sapiens cDNA FLJ11812 fis, clone
HEMBA1006364 Hs.23837 0.28 0.21 0.28 0.49 0.29 0.21 0.26 0.28 0.21
Ets homologous factor EHF Hs.182339 0.28 0.31 0.26 0.26 0.20 0.32 0.27 0.30 0.29 0.30
Dual specificity phosphatase 1 DUSP1 Hs.171695 0.27 0.11 0.28 0.09 0.10 0.10 0.16 0.21 0.41 0.94
Tubulin, ·3 TUBA3 Hs.433394 0.25 0.12 0.12 0.10 0.35 0.37 0.42
Small nuclear ribonucleoprotein polypeptide N SNRPN Hs.48375 0.24 0.22 0.12 0.50 0.33 0.13 0.15
Zinc finger protein 217 ZNF217 Hs.155040 0.23 0.24 0.24 0.24 0.14 0.20 0.24 0.25 0.31
Hypothetical protein BM-002 BM-002 Hs.367646 0.23 0.32 0.09 0.21 0.24 0.22 0.29
Amphiregulin (schwannoma-derived growth 
factor) AREG Hs.270833 0.20 0.24 0.21 0.14 0.16 0.20 0.18 0.24
Cyclin-dependent kinase inhibitor 1A
(p21, Cip1) CDKN1A Hs.179665 0.17 0.16 0.12 0.14 0.14 0.10 0.08 0.19 0.21 0.39
CCR4-NOT transcription complex, subunit 7 CNOT7 Hs.380963 0.17 0.19 0.12 0.13 0.18 0.15 0.16 0.22 0.18 0.15
Serine (or cysteine) proteinase inhibitor,
clade B (ovalbumin), member 2 SERPINB2 Hs.75716 0.13 0.71 0.03 0.03 0.05 0.03 0.04 0.04
Serum amyloid A1 SAA1 Hs.332053 0.12 0.10 0.11 0.15
Hypothetical protein FLJ10154 FLJ10154 Hs.179972 0.10 0.10 0.07 0.07 0.06 0.06 0.12 0.17 0.16 0.10
KIAA0669 gene product KIAA0669 Hs.52526 0.07 0.04 0.05 0.05 0.07 0.07 0.07 0.10
C. Genes upregulated in primary isolates only
Name Symbol Unigene ID MV
all/hPDC
MV
ATCC/
hPDC
MV PI/
hPDC
BxPC-3 AsPC-1 Capan-1 Capan-2HPAF PI1 PI3 PI4 PI5
Importin 7 IPO7 Hs.5151 2.31 1.51 3.11 1.90 1.25 1.25 1.63 3.33 3.22 3.37 2.52
Hypothetical protein DKFZp434L142 DKFZp434L142 Hs.323583 2.23 0.95 3.52 0.81 0.95 1.16 0.87 4.94 4.68 3.37 1.08
Transmembrane 4 superfamily member 7 TM4SF7 Hs.26518 3.12 1.90 4.03 1.86 2.07 1.76 2.31 5.57 4.04 4.20
Insulin-like-growth-factor-binding protein 6 IGFBP6 Hs.274313 3.34 2.18 4.50 5.89 0.87 0.81 1.15 5.44 4.80 3.74 4.02
Chromosome 8 open reading frame 4 C8orf4 Hs.283683 3.32 0.88 4.53 0.43 1.34 1.07 2.96 3.62 10.49
Insulin-like-growth-factor-binding protein 3 IGFBP3 Hs.77326 5.29 1.68 8.89 2.87 1.93 1.08 0.84 6.25 9.80 12.39 7.12
Vimentin VIM Hs.297753 5.21 1.25 9.17 0.34 3.70 0.63 0.34 6.60 10.34 12.25 7.51
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Table 1 (continued)
D. Genes downregulated in primary isolates only
Name Symbol Unigene ID MV all/
hPDC
MV
ATCC/
hPDC
MV PI/
hPDC
BxPC-3 AsPC-1 Capan-1 Capan-2 HPAF2 PI1 PI3 PI4 PI5
CD24 antigen CD24 Hs.375108 0.41 0.59 0.03 0.70 0.38 0.89 0.40 0.03 0.03 0.02
Secretory leukocyte protease
Inhibitor (antileukoproteinase) SLPI Hs.251754 0.56 0.79 0.28 0.79 0.94 1.07 0.41 0.71 0.56 0.15 0.13 0.27
Cadherin 1, E-cadherin CDH1 Hs.194657 0.58 0.83 0.28 1.11 0.65 1.00 0.79 0.59 0.49 0.17 0.20 0.25
E. Genes upregulated in ATCC cell lines only
Name Symbol Unigene ID MV all/
hPDC
MV
ATCC/
hPDC
MV PI/
hPDC
BxPC-3 AsPC-1 Capan-1 Capan-2 HPAF2 PI1 PI3 PI4 PI5
Frizzled 6 FZD6 Hs.114218 3.12 3.55 1.25 6.62 3.97 3.90 3.88 3.75 1.64 0.87 1.11 1.37
The fold change of expression of the tumor cell lines vs. the cell line hPDC. MV/hPDC = fold change of the mean of the expression value of the tumor cell lines vs. hPDC.
Fig. 2. Functional categories of differential-
ly expressed genes. Numbers above the bars
indicate the number of genes within the
group.
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Overexpression of TMSB10 in Human Pancreatic
Carcinoma
Expression changes observed in cell lines are not neces-
sarily represented in primary tissues also. Therefore, out of
the 122 upregulated genes we selected TMSB10 to analyze
the expression of its protein in human pancreatic adenocar-
cinoma by using a polyclonal antibody and immunohisto-
chemistry. Moreover, TMSB10 is associated with cellular
proliferation in a number of cancers indicating that overex-
pression of this gene might be a causal event [13].
TMSB10 expression was detected in endothelium,
smooth muscle cells, neuronal cells, and strongly in mac-
rophages, both in tumor and in normal tissues. In 49 of
the 54 (90.7%) ductal adenocarcinomas examined, immu-
noreactivity for TMSB10 was detected in the tumor cells
(fig. 3). Conversely, in none of the 10 sections of normal
pancreatic tissue could TMSB10 be shown by means of
immunohistochemistry. In 24 of 54 (44.4%) cases, we
detected staining in the stroma. The correlation between
staining in the tumor and staining in stroma cells, which
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Fig. 3. Immunohistochemical staining of non-neoplastic pancreas (A), ductal pancreatic adenocarcinoma (B) and
stromal tissue within a pancreatic adenocarcinoma (C) using TMSB10 antibody. Examples for normal ducts (d),
endothelial cells (e) and stromal cells (s) are indicated with arrows. The pancreatic adenocarcinoma B was scored as
2+ and the sample C as 3+. A, B 100!, C 200! magnification. D–F Strong (D), moderate (E) and weak (F) staining of
pancreatic adenocarcinoma samples.
Table 2. Genes known to be involved in tumorigenesis in various tissues
Name Symbol Unigene ID Function Involved
in cancer
Involved in
pancreatic
cancer
Reference
Prefoldin 5 PFDN5 Hs.288856 Chaperone Yes [25]
Thymosin ß-10 TMSB10 Hs.76293 Proliferation Yes [13, 22, 23]
Calmodulin 1 CALM1 Hs.374441 Signal transduction Yes No [26]
Cellular apoptosis susceptibility
protein CSE1L/CAS CSE1L Hs.90073 Proliferation and apoptosis Yes No [27]
Lymphocyte antigen 6 LY6E Hs.77667 Signal transduction Yes No [28]
Cyclin-dependent kinase 4 CDK4 Hs.95577 Cell cycle Yes No [29]
ADAM9 ADAM9 Hs.2442 Proliferation Yes Yes [30]
Prohibitin PHB Hs.75323 Proliferation Yes No [31]
Cyclin-dependent kinase inhibitor 1 CDKN1A Hs.179665 Apoptosis Yes No [32]
E-cadherin CDH1 Hs.194657 Cell adhesion Yes Yes [16, 18, 33, 34]
Table 3. TMSB10 protein expression in pancreatic ductal adenocar-
cinoma cells (n = 55) and in stroma cells within the tumors
Tumor positive Tumor negative
Stroma positive 20 2
Stroma negative 28 5
p = 0.411, Fisher’s exact test.
was not significant, is shown in table 3. Furthermore, we
could not find a significant correlation between the posi-
tivity or the intensity of expression of TMSB10 and post-
operative survival of patients. However, we observed that
TMSB10 is highly expressed within well- and poorly-dif-
ferentiated carcinomas (G1 and G3), whereas the majori-
ty of moderately differentiated tumors (G2) expressed
TMSB10 only moderately.
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Discussion
The DNA microarray technology is widely used as a
powerful tool to investigate the mRNA expression pattern
of various tissues and cell types. For tissues that are diffi-
cult to access or scarcely available, cell lines are a helpful
alternative. This is especially true for pancreatic cancer. It
is well known that cells change both their morphology and
their expression pattern when isolated from their parent
organism, the human body [14, 15]. However, analysis of
cell lines might circumvent the need for microdissection
of tissues and, furthermore, allow the characterization of
the most adequate model system for further analysis of
differentially expressed genes.
Upregulation of growth factors, cytokines, receptors,
extracellular matrix proteins and numerous other pro-
teins is a common event in carcinogenesis. We corrobo-
rated this in the pancreatic tumor cell lines analyzed in
this study, finding 122 genes upregulated and only 18
downregulated in respect to benign cells.
Apart from the genes differentially regulated in all cell
lines, we found 7 genes upregulated and 3 genes downreg-
ulated in the primary isolates only, while 1 gene, frizzled
6, was upregulated only in the ATCC cell lines. E-cadher-
in, 1 of the 3 genes downregulated in primary cells, is the
main adhesion molecule of epithelia, and it has been
implicated in carcinogenesis because it is frequently lost
in human epithelial cancers [16]. It is known to act as a
strong invasion suppressor in experimental tumor cell sys-
tems [17]. Partial or complete loss of E-cadherin expres-
sion correlates with malignancy in human cancers [18].
Interestingly, we found downregulation in the primary
isolates, but not in the ATCC cells, which may support the
assumption that primary cell lines reflect the biological
features of the tumor more than established cell lines.
The mesenchymal intermediate filament marker vi-
mentin is strongly expressed in invasive pancreatic carci-
nomas [19] and generally expressed in pancreatic carcino-
ma cell lines [20]. The overexpression in primary isolates
suggests a relative importance of this filament in cells
adapting to the new environment petridish; it seems to be
of less importance after adjustment to the different needs
of the cells in vitro. Most genes, however, show a compa-
rable degree of expression. This might support the as-
sumption that cells adapt very quickly when isolated and
transferred into medium. If they would not, they could
not replicate and survive. Within the large set of genes
implied in cellular proliferation and identified by the
GeneChip analysis we were especially interested in the
analysis of TMSB10. The ß-thymosins are a family of
related peptides known to be present in a wide variety of
mammalian and other vertebrate cells and tissues.
TMSB10 mRNA is overexpressed in germ cell tumors of
different histological types, breast-, ovarian-, uterine car-
cinomas, colon, thyroid and esophageal carcinoma cell
lines [13, 21, 22]. It has also been shown that TMSB10
plays a critical role in the regulation of anchorage-inde-
pendent growth and assembly of actin filaments [23]. Fur-
thermore upregulation of TMSB10 was identified in the
breast cancer cell line MCF-7 in the course of treatment
with 5-fluorouracil, tomudex and oxaliplatin, respective-
ly. TMSB10 expression is also elevated in the 5-fluoroura-
cil-resistant colon cancer cell line H630R10 [24] implying
a role for TMSB10 within the reaction of cells on toxic
compounds.
In conclusion we have reported for the first time the
expression of TMSB10 in pancreatic carcinoma.
TMSB10 might play a general role in human carcinogene-
sis and in pancreatic carcinomas especially. Our finding
that TMSB10 is strongly expressed in stroma cells of pan-
creatic carcinoma supports the suggestion of Santelli et al.
[23] who claim a critical role for TMSB10 in the regula-
tion of anchorage-independent growth and assembly of
actin filaments.
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